TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05192889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intravenously (IV) or Intrathecal (IT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intravenously (IV), oral (PO), or Intrathecal (IT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given oral (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given oral (PO) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given oral (PO) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: Given Intrathecal (IT).
Study: NCT06016959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietetic intervention
Description: Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition \& also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
Study: NCT05192889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: Given Intrathecal (IT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: See detailed description section.
Study: NCT06086795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole eggs
Description: 3 large whole eggs per day for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg yolks
Description: 3 large egg equivalent of egg yolks per day for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg whites
Description: 3 large egg equivalent of egg whites per day for 4 weeks
Study: NCT06280924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Exercise
Description: Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive standard care
Study: NCT04745364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 4-week Bharatanatyam course from the organization Mindful Kala
Description: The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 4-week Bharatanatyam course from the organization Mindful Kala
Description: The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
Study: NCT06219889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequency of neurochecks
Description: the frequency with which a patient is awakened to perform serial examinations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Frequency of neurochecks
Description: the frequency with which a patient is awakened to perform serial examinations
Study: NCT05865028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-157
Description: Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
Study: NCT05574686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Blood Pressure Monitoring and Food Insecurity
Description: Telehealth Blood Pressure Monitoring and Food Insecurity
Study: NCT05734027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sectional matrix
Description: The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sectional matrix
Description: The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential matrix
Description: Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circumferential matrix
Description: Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect
Study: NCT04773392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily Tacrolimus
Description: Within 48 hours of transplantation, immediate release tacrolimus (IRT) (0.1 mg/kg /day) will be administered twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once-daily envarsus XR
Description: Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)
Description: Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)
Description: Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, prednisone
Description: Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, prednisone
Description: Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)
Description: Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine (1-3 mg/kg) will be administered once a day.
Study: NCT05383469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Classical massage including superficial and deep stroking and friction methods for the lower extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Symmetrical biphasic current at a frequency of 30-85 Hz

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
Study: NCT06024941

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
Study: NCT06377176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: the intervention group underwent ten sessions of twice-weekly mother and infant massage therapy for five weeks.
Study: NCT06016959

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet sheet (placebo)
Description: Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton \& Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
Study: NCT06409806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECOG Array
Description: The patient will undergo their intracranial neurosurgical procedure as planned, using conventional brain retractors and neurosurgical equipment.~Standard neuromonitoring (EEG, MEP, SSEP) will be placed after the induction of neuroanaesthesia if indicated. Additional to whatever conventional EMBRI neuromonitoring is used, intraoperatively an ECoG array will be positioned under the retractor by the operating surgeon. Further electrode arrays may be placed on the cortical surface remote from the retractor as needed to establish a reference.~Typically we anticipate one ECoG array under the retractor blade with a reference array on an area of unretracted brain.
Study: NCT06124911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training (3x5)
Description: Leg Press resistance training at 60% one-rep-max for three sets of five repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training (3x5)
Description: Leg Press resistance training at 60% one-rep-max for three sets of five repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training (5x5)
Description: Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
Study: NCT05979493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 30cc IM injection in each quadratus lumborum muscle (60cc total).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 30cc IM injection in each quadratus lumborum muscle (60cc total).
Study: NCT04803318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
Description: Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.
Study: NCT05300503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehome Monitoring
Description: Participants are enrolled into the Telehome Monitoring program
Study: NCT05119777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HArmonyCa Injectable Gel
Description: Subdermal or deep dermal injection
Study: NCT06453148

Intervention type: OTHER
Intervention: Non-interventions
Description: Usual care evaluations
Study: NCT05443308

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral [15O]H2O PET before and after diamox infusion
Description: Cerebral \[15O\]H2O PET before and after diamox infusion

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral [15O]H2O PET before and after diamox infusion
Description: Cerebral \[15O\]H2O PET before and after diamox infusion

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral [15O]H2O PET before and after diamox infusion
Description: Cerebral \[15O\]H2O PET before and after diamox infusion
Study: NCT05132153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: will be given by nebulization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: will be given by nebuliztion
Study: NCT05136586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control and biofeedback post OSCE
Description: 6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control and control post OSCE
Description: 6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction.
Study: NCT06296147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The interventions are for supportive care ONLY.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The interventions are for supportive care ONLY.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Patch
Description: The interventions are for supportive care ONLY.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Patch
Description: The interventions are for supportive care ONLY.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participant will undergo a transperineal prostate biopsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participant will undergo a transperineal prostate biopsy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participant will undergo a transperineal prostate biopsy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participant will undergo a transperineal prostate biopsy.
Study: NCT05195164

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention

Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention
Study: NCT06117930

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05119647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombus Aspiration Catheter(Ton-bridgeMT)
Description: Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
Study: NCT06517082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.
Study: NCT05387083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose TP-05
Description: Healthy Volunteers will receive a single low dose of TP-05 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose TP-05
Description: Healthy Volunteers will receive a single high dose of TP-05 on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Healthy Volunteers will receive a single dose of placebo on Day 1.
Study: NCT05750251

Intervention type: PROCEDURE
Intervention: levator muscle resection surgery
Description: conventional ptosis surgery

Intervention type: PROCEDURE
Intervention: Müller's muscle-conjuctival resection surgery
Description: conventional ptosis surgery

Intervention type: PROCEDURE
Intervention: full-thickness anterior blepharotomy surgery
Description: conventional eyelid retraction surgery
Study: NCT05306925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine
Description: The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
Study: NCT02988297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: Nebulized RNS60 will be administered by daily inhalation for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized Placebo will be administered by daily inhalation for 24 weeks.
Study: NCT05045768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Gelsectan, Devintec Sagl)
Description: Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
Study: NCT06124911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training (5x5)
Description: Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
Study: NCT05830058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT